Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4F2 | P78329 | 1/20 | 0.54 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | RET | P07949 | 1/20 | 0.36 |
| ▸ | KIF5B | P33176 | 1/20 | 0.36 |
| ▸ | TTR | P02766 | 1/20 | 0.36 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.35 |
| ▸ | REN | P00797 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13191098 | 0.85 | CYP4F2 (0.55) | CYP4F2CYP4A11L3MBTL1 | |
| SCHEMBL3073300 | 0.84 | TTR (0.40) | CYP4F2CYP4A11L3MBTL1TDP1KDM4E | |
| SCHEMBL3977294 | 0.84 | L3MBTL1 (0.39) | CYP4F2CYP4A11L3MBTL1TDP1KDM4E | |
| SCHEMBL16471629 | 0.83 | CYP4F2 (0.53) | CYP4F2CYP4A11L3MBTL1TDP1KDM4E | |
| SCHEMBL2890956 | 0.83 | CYP4F2 (0.57) | CYP4F2CYP4A11NPC1POLBRAB9A | |
| SCHEMBL7952850 | 0.82 | CYP3A4 (0.44) | TDP1ALDH1A1TTR | |
| SCHEMBL2810242 | 0.82 | REN (0.48) | L3MBTL1TDP1KDM4ENPC1POLB | |
| SCHEMBL29521379 | 0.82 | REN (0.48) | L3MBTL1TDP1KDM4ENPC1POLB | |
| SCHEMBL3080203 | 0.82 | TSHR (0.44) | CYP4F2CYP4A11L3MBTL1TDP1KDM4E | |
| SCHEMBL28632760 | 0.81 | CYP4F2 (0.51) | CYP4F2CYP4A11L3MBTL1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2687518-B1 | NITROGEN-CONTAINING SATURATED HETEROCYCLIC COMPOUND | MITSUBISHI TANABE PHARMA CORP (JP) | 2017-11-01 | — | — | EP | disclosed |
| US-9556159-B2 | Renin inhibitor | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2017-01-31 | — | — | US | disclosed |
| US-20160145220-A1 | NITROGEN-CONTAINING SATURATED HETEROCYCLIC COMPOUND | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2016-05-26 | — | — | US | disclosed |
| US-9278944-B2 | Nitrogen-containing saturated heterocyclic compound | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2016-03-08 | — | — | US | disclosed |
| EP-2933248-A1 | NOVEL RENIN INHIBITOR | Mitsubishi Tanabe Pharma Corporation (JP) | 2015-10-21 | — | — | EP | disclosed |
| US-20150232459-A1 | NOVEL RENIN INHIBITOR | SHANGHAI PHARMACEUTICALS HOLDING CO., LTD. (CN) | 2015-08-20 | — | — | US | disclosed |
| EP-2687518-A1 | NITROGEN-CONTAINING SATURATED HETEROCYCLIC COMPOUND | Mitsubishi Tanabe Pharma Corporation (JP) | 2014-01-22 | — | — | EP | disclosed |
| US-20140011807-A1 | NITROGEN-CONTAINING SATURATED HETEROCYCLIC COMPOUND | SHANGHAI PHARMACEUTICALS HOLDING CO., LTD. (CN) | 2014-01-09 | — | — | US | disclosed |
| WO-2012124775-A1 | NITROGEN-CONTAINING SATURATED HETEROCYCLIC COMPOUND | 田辺三菱製薬株式会社 (JP) | 2012-09-20 | — | — | WO | disclosed |
| US-7842688-B2 | Organic compounds | NOVARTIS PHARMA AG (CH) | 2010-11-30 | — | — | US | disclosed |
| WO-2009053277-A1 | ASPARTYL PROTEASE INHIBITORS | MEDIVIR AB (SE) | 2009-04-30 | — | — | WO | disclosed |
| US-20090012055-A1 | Organic compounds | HEROLD PETER | 2009-01-08 | — | — | US | disclosed |
| WO-2008107365-A1 | NEW COMPOUNDS | MEDIVIR AB (SE) | 2008-09-12 | — | — | WO | disclosed |
| WO-2008107365-A1 | NEW COMPOUNDS | MEDIVIR AB (SE) | 2008-09-12 | — | — | WO | disclosed |
| EP-1961752-A2 | Piperidine Compounds | Speedel Experimenta AG (CH) | 2008-08-27 | — | — | EP | disclosed |
| US-20070010511-A1 | Organic compounds | NOVARTIS PHARMA AG (CH) | 2007-01-11 | — | — | US | disclosed |
| EP-1707202-A1 | Organic compounds | Speedel Experimenta AG (CH) | 2006-10-04 | — | — | EP | disclosed |
| EP-1670760-A1 | ORGANIC COMPOUNDS | Speedel Experimenta AG (CH) | 2006-06-21 | — | — | EP | disclosed |
| WO-2005061457-A1 | ORGANIC COMPOUNDS | SPEEDEL EXPERIMENTA AG (CH) | 2005-07-07 | — | — | WO | disclosed |
| WO-2005061457-A1 | ORGANIC COMPOUNDS | SPEEDEL EXPERIMENTA AG (CH) | 2005-07-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140011807-A1 | NITROGEN-CONTAINING SATURATED HETEROCYCLIC COMPOUND | REN, AGTR1, AGTR2 | CYP4F2 448/4885CYP4A11 42/4885L3MBTL1 3732/4885 |
| US-20090012055-A1 | Organic compounds | REN, ACE, ACE2 | CYP4F2 35/4885CYP4A11 47/4885L3MBTL1 4797/4885 |
| US-20070010511-A1 | Organic compounds | REN, ACE, ACE2 | CYP4F2 35/4885CYP4A11 47/4885L3MBTL1 4797/4885 |
| US-20150232459-A1 | NOVEL RENIN INHIBITOR | REN, AGTR1, ACE | CYP4F2 484/4885CYP4A11 125/4885L3MBTL1 4668/4885 |
| US-20160145220-A1 | NITROGEN-CONTAINING SATURATED HETEROCYCLIC COMPOUND | REN, AGTR1, AGTR2 | CYP4F2 448/4885CYP4A11 42/4885L3MBTL1 3732/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.